+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Actinic Keratosis Drugs Market 2021-2025

  • PDF Icon

    Report

  • 120 Pages
  • April 2021
  • Region: Global
  • TechNavio
  • ID: 5117604
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the actinic keratosis drugs market and it is poised to grow by $709.82 million during 2021-2025, progressing at a CAGR of about 4% during the forecast period. The report on the actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of actinic keratosis and the threat of conversion to fatal disease.

The actinic keratosis drugs market analysis includes the product segment and geographic landscape.

The actinic keratosis drugs market is segmented as below:

By Product
  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs

By Geography
  • North America
  • APAC
  • Europe
  • ROW

This study identifies the availability of combination therapy as one of the prime reasons driving the actinic keratosis drugs market growth during the next few years.

The report on actinic keratosis drugs market covers the following areas:
  • Actinic keratosis drugs market sizing
  • Actinic keratosis drugs market forecast
  • Actinic keratosis drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading actinic keratosis drugs market vendors that include 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Cipher Pharmaceuticals Inc., Hill Dermaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vidac Pharma. Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

Executive Summary
  • Market Overview

Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Nucleoside metabolic inhibitors - Market size and forecast 2020-2025
  • Immunomodulators - Market size and forecast 2020-2025
  • Photosensitizers - Market size and forecast 2020-2025
  • NSAIDs - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape
Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • APAC - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape
  • Overview
  • Landscape disruption

Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cipher Pharmaceuticals Inc.
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vidac Pharma

Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of ExhibitsExhibits1: Key Finding 1Exhibits2: Key Finding 2Exhibits3: Key Finding 3Exhibits4: Key Finding 5Exhibits5: Key Finding 6Exhibits6: Key Finding 7Exhibits7: Key Finding 8Exhibits8: Parent marketExhibits9: Market characteristicsExhibits10: Offerings of vendors included in the market definitionExhibits11: Market segmentsExhibits12: Global - Market size and forecast 2020 - 2025 ($ million)Exhibits13: Global market: Year-over-year growth 2020 - 2025 (%)Exhibits14: Five forces analysis 2020 & 2025Exhibits15: Bargaining power of buyersExhibits16: Bargaining power of suppliersExhibits17: Threat of new entrantsExhibits18: Threat of substitutesExhibits19: Threat of rivalryExhibits20: Market condition - Five forces 2020Exhibits21: Product - Market share 2020-2025 (%)Exhibits22: Comparison by ProductExhibits23: Nucleoside metabolic inhibitors - Market size and forecast 2020-2025 ($ million)Exhibits24: Nucleoside metabolic inhibitors - Year-over-year growth 2020-2025 (%)Exhibits25: Immunomodulators - Market size and forecast 2020-2025 ($ million)Exhibits26: Immunomodulators - Year-over-year growth 2020-2025 (%)Exhibits27: Photosensitizers - Market size and forecast 2020-2025 ($ million)Exhibits28: Photosensitizers - Year-over-year growth 2020-2025 (%)Exhibits29: NSAIDs - Market size and forecast 2020-2025 ($ million)Exhibits30: NSAIDs - Year-over-year growth 2020-2025 (%)Exhibits31: Market opportunity by ProductExhibits32: Customer landscapeExhibits33: Market share by geography 2020-2025 (%)Exhibits34: Geographic comparisonExhibits35: North America - Market size and forecast 2020-2025 ($ million)Exhibits36: North America - Year-over-year growth 2020-2025 (%)Exhibits37: APAC - Market size and forecast 2020-2025 ($ million)Exhibits38: APAC - Year-over-year growth 2020-2025 (%)Exhibits39: Europe - Market size and forecast 2020-2025 ($ million)Exhibits40: Europe - Year-over-year growth 2020-2025 (%)Exhibits41: ROW - Market size and forecast 2020-2025 ($ million)Exhibits42: ROW - Year-over-year growth 2020-2025 (%)Exhibits43: Key leading countriesExhibits44: Market opportunity by geography ($ million)Exhibits45: Impact of drivers and challengesExhibits46: Vendor landscapeExhibits47: Landscape disruptionExhibits48: Industry risksExhibits49: Vendors coveredExhibits50: Market positioning of vendorsExhibits51: 3M Co. - OverviewExhibits52: 3M Co. - Business segmentsExhibits53: 3M Co. - Key offeringsExhibits54: 3M Co. - Key customersExhibits55: 3M Co. - Segment focusExhibits56: Almirall SA - OverviewExhibits57: Almirall SA - Product and serviceExhibits58: Almirall SA - Key offeringsExhibits59: Almirall SA - Key customersExhibits60: Almirall SA - Segment focusExhibits61: Bausch Health Companies Inc. - OverviewExhibits62: Bausch Health Companies Inc. - Business segmentsExhibits63: Bausch Health Companies Inc. - Key offeringsExhibits64: Bausch Health Companies Inc. - Key customersExhibits65: Bausch Health Companies Inc. - Segment focusExhibits66: Biofrontera AG - OverviewExhibits67: Biofrontera AG - Product and serviceExhibits68: Biofrontera AG - Key offeringsExhibits69: Biofrontera AG - Key customersExhibits70: Biofrontera AG - Segment focusExhibits71: Cipher Pharmaceuticals Inc. - OverviewExhibits72: Cipher Pharmaceuticals Inc. - Business segmentsExhibits73: Cipher Pharmaceuticals Inc. - Key offeringsExhibits74: Cipher Pharmaceuticals Inc. - Key customersExhibits75: Cipher Pharmaceuticals Inc. - Segment focusExhibits76: Hill Dermaceuticals Inc. - OverviewExhibits77: Hill Dermaceuticals Inc. - Product and serviceExhibits78: Hill Dermaceuticals Inc. - Key offeringsExhibits79: Hill Dermaceuticals Inc. - Key customersExhibits80: Hill Dermaceuticals Inc. - Segment focusExhibits81: Mylan NV - OverviewExhibits82: Mylan NV - Business segmentsExhibits83: Mylan NV - Key offeringsExhibits84: Mylan NV - Key customersExhibits85: Mylan NV - Segment focusExhibits86: Sun Pharmaceutical Industries Ltd. - OverviewExhibits87: Sun Pharmaceutical Industries Ltd. - Business segmentsExhibits88: Sun Pharmaceutical Industries Ltd. - Key offeringsExhibits89: Sun Pharmaceutical Industries Ltd. - Key customersExhibits90: Sun Pharmaceutical Industries Ltd. - Segment focusExhibits91: Teva Pharmaceutical Industries Ltd. - OverviewExhibits92: Teva Pharmaceutical Industries Ltd. - Business segmentsExhibits93: Teva Pharmaceutical Industries Ltd. - Key offeringsExhibits94: Teva Pharmaceutical Industries Ltd. - Key customersExhibits95: Teva Pharmaceutical Industries Ltd. - Segment focusExhibits96: Vidac Pharma - OverviewExhibits97: Vidac Pharma - Business segmentsExhibits98: Vidac Pharma - Key offeringsExhibits99: Vidac Pharma - Key customersExhibits100: Vidac Pharma - Segment focusExhibits101: Currency conversion rates for US$Exhibits102: Research MethodologyExhibits103: Validation techniques employed for market sizingExhibits104: Information sourcesExhibits105: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global actinic keratosis drugs market: 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Cipher Pharmaceuticals Inc., Hill Dermaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vidac Pharma.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the availability of combination therapy.'

According to the report, one of the major drivers for this market is the high prevalence of actinic keratosis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Cipher Pharmaceuticals Inc.
  • Hill Dermaceuticals Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vidac Pharma